TY  - JOUR

T1  - Tralokinumab provides clinically meaningful responses at week 16 in adults with moderate-to-severe atopic dermatitis who do not achieve IGA 0/1

JO  - American Journal of Clinical Dermatology

UR  - https://eprints.whiterose.ac.uk/id/eprint/207863

UR  - http://dx.doi.org/10.1007/s40257-023-00817-0

PY  - 2023/10/07

AU  - Simpson EL

AU  - Blauvelt A

AU  - Silverberg JI

AU  - Cork MJ

AU  - Katoh N

AU  - Mark T

AU  - Schneider SKR

AU  - Wollenberg A

ED  - 

DO  - DOI: 10.1007/s40257-023-00817-0

PB  - Springer Science and Business Media LLC

VL  - 25

SP  - 139

EP  - 148

Y2  - 2025/11/05

ER  -